Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Shares Outstanding (Weighted Average)
Others
Ratios

RedHill Biopharma (RDHL) Revenue (2016 - 2023)

Historic Revenue for RedHill Biopharma (RDHL) over the last 12 years, with Q2 2023 value amounting to $1.8 million.

  • RedHill Biopharma's Revenue fell 9021.04% to $1.8 million in Q2 2023 from the same period last year, while for Dec 2024 it was $1.8 million, marking a year-over-year decrease of 9012.81%. This contributed to the annual value of $8043.0 billion for FY2024, which is 12316988468.61% up from last year.
  • RedHill Biopharma's Revenue amounted to $1.8 million in Q2 2023, which was down 9021.04% from $3.6 million recorded in Q1 2023.
  • In the past 5 years, RedHill Biopharma's Revenue registered a high of $22.1 million during Q4 2021, and its lowest value of $1.1 million during Q1 2020.
  • Its 5-year average for Revenue is $12.4 million, with a median of $15.3 million in 2022.
  • In the last 5 years, RedHill Biopharma's Revenue soared by 184839.02% in 2021 and then plummeted by 9021.04% in 2023.
  • Over the past 5 years, RedHill Biopharma's Revenue (Quarter) stood at $1.6 million in 2019, then skyrocketed by 1249.75% to $21.5 million in 2020, then grew by 2.84% to $22.1 million in 2021, then crashed by 42.01% to $12.8 million in 2022, then plummeted by 85.97% to $1.8 million in 2023.
  • Its Revenue stands at $1.8 million for Q2 2023, versus $3.6 million for Q1 2023 and $12.8 million for Q4 2022.